Wedbush Predicts Arcus Biosciences’ Q2 Earnings (NYSE:RCUS)

Arcus Biosciences, Inc. (NYSE:RCUSFree Report) – Research analysts at Wedbush dropped their Q2 2025 earnings per share estimates for shares of Arcus Biosciences in a research note issued on Wednesday, May 7th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of ($1.11) per share for the quarter, down from their previous estimate of ($1.01). Wedbush has a “Outperform” rating and a $33.00 price target on the stock. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.15) per share. Wedbush also issued estimates for Arcus Biosciences’ Q3 2025 earnings at ($1.13) EPS, Q4 2025 earnings at ($1.15) EPS, FY2025 earnings at ($4.53) EPS, FY2026 earnings at ($4.32) EPS, FY2027 earnings at ($3.60) EPS, FY2028 earnings at ($0.52) EPS and FY2029 earnings at $3.37 EPS.

Other analysts have also issued reports about the company. HC Wainwright raised Arcus Biosciences from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $18.00 to $24.00 in a research report on Wednesday, February 26th. Barclays cut their target price on Arcus Biosciences from $29.00 to $14.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 23rd. Morgan Stanley reduced their target price on Arcus Biosciences from $24.00 to $22.00 and set an “overweight” rating for the company in a research note on Friday. Wells Fargo & Company dropped their price target on shares of Arcus Biosciences from $29.00 to $26.00 and set an “overweight” rating for the company in a research note on Wednesday. Finally, The Goldman Sachs Group reduced their price objective on shares of Arcus Biosciences from $15.00 to $13.00 and set a “neutral” rating on the stock in a research note on Thursday. Two research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Arcus Biosciences has an average rating of “Moderate Buy” and a consensus price target of $25.67.

View Our Latest Stock Report on RCUS

Arcus Biosciences Stock Performance

Shares of RCUS stock opened at $8.28 on Friday. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.24 and a quick ratio of 5.24. The company’s fifty day moving average price is $8.40 and its two-hundred day moving average price is $12.39. The firm has a market capitalization of $876.73 million, a P/E ratio of -2.63 and a beta of 0.88. Arcus Biosciences has a 12 month low of $6.50 and a 12 month high of $18.98.

Arcus Biosciences (NYSE:RCUSGet Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($1.14) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.12). The firm had revenue of $28.00 million for the quarter, compared to analyst estimates of $38.61 million. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The company’s revenue for the quarter was down 80.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.05) earnings per share.

Insider Activity at Arcus Biosciences

In other news, Director Yasunori Kaneko purchased 20,000 shares of the stock in a transaction dated Thursday, February 27th. The stock was acquired at an average price of $10.06 per share, for a total transaction of $201,200.00. Following the completion of the transaction, the director now owns 28,400 shares of the company’s stock, valued at approximately $285,704. The trade was a 238.10 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Terry J. Rosen acquired 19,800 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The stock was purchased at an average price of $10.18 per share, for a total transaction of $201,564.00. Following the completion of the transaction, the chief executive officer now owns 2,554,160 shares in the company, valued at $26,001,348.80. The trade was a 0.78 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 12.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Arcus Biosciences by 2.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,007 shares of the company’s stock worth $506,000 after buying an additional 833 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Arcus Biosciences by 2.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 43,685 shares of the company’s stock worth $668,000 after acquiring an additional 1,117 shares during the period. R Squared Ltd bought a new position in shares of Arcus Biosciences in the fourth quarter worth $26,000. Teacher Retirement System of Texas increased its holdings in shares of Arcus Biosciences by 19.2% during the fourth quarter. Teacher Retirement System of Texas now owns 14,952 shares of the company’s stock valued at $223,000 after purchasing an additional 2,410 shares during the period. Finally, Handelsbanken Fonder AB increased its holdings in shares of Arcus Biosciences by 11.2% during the fourth quarter. Handelsbanken Fonder AB now owns 24,800 shares of the company’s stock valued at $369,000 after purchasing an additional 2,500 shares during the period. Institutional investors own 92.89% of the company’s stock.

Arcus Biosciences Company Profile

(Get Free Report)

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.

Read More

Earnings History and Estimates for Arcus Biosciences (NYSE:RCUS)

Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.